October 2022 in “The Journal of Clinical Pharmacology” Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
14 citations
,
February 2011 in “Drug Metabolism and Disposition” Ketoconazole increases finasteride's effectiveness and lifespan in the body.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
1 citations
,
August 2025 in “Journal of Neonatal Surgery” The nanogel with Ciclopirox Olamine is a promising treatment for skin yeast infections.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
1 citations
,
November 2025 in “International Journal of Clinical Pharmacy” Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
34 citations
,
April 1982 in “BMJ” April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
June 2018 in “Reactions Weekly” A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
Diphenyl cresyl phosphate has low toxicity but can harm the liver, kidneys, adrenal glands, and testicles at high doses.
Baricitinib works better than methotrexate for severe alopecia areata.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
July 2005 in “SKINmed/Skinmed” BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
Cyproterone acetate with ethynyl estradiol significantly improved acne and seborrhea in women, but was less effective for hair loss and excessive hair growth.